Printer Friendly

SANDOZ PHARMACEUTICALS INAUGURATES A STATE-OF-THE-ART QUALITY ASSURANCE AND COMPLIANCE FACILITY

 SANDOZ PHARMACEUTICALS INAUGURATES
 A STATE-OF-THE-ART QUALITY ASSURANCE AND COMPLIANCE FACILITY
 EAST HANOVER, N.J., June 5 /PRNewswire/ -- Sandoz Pharmaceuticals Corporation today marked the second major phase of a nearly $1 billion, decade-long expansion program with the opening of a state-of-the-art quality control laboratory and office facility.
 With three floors, each almost the size of a football field, the $20 million facility known as Building 430 will serve as the new headquarters for 120 employees from the Quality Assurance and Compliance groups who ensure that Sandoz Pharmaceuticals products and services meet all Sandoz specifications, U.S. government regulations and customer needs and expectations.
 "Building 430 is a celebration of the human spirit and a visible statement of our commitment to quality," said company president and chief executive officer, Jacques F. Rejeange. "All along the way, our associates have been involved in the planning and design of this cutting-edge facility. From the beginning, the company and its employees have been dedicated to one goal -- the quality of Sandoz products and services."
 Gregory B. Bennett, vice president of Quality U.S., said the new building was developed in order to accommodate the growth the department has experienced over the past decade and the continued expansion that will take place at Sandoz during the 1990s.
 He noted that the staff had grown from 32 to 120 over the past ten years and said the relocation of the employees will allow the company to renovate their department's current building, which is located near Building 430, and add additional research staff.
 Building 430 affords 100,000 gross square feet of floor space. At a cost of more than $20 million, the modern glass and concrete structure is the culmination of eight years of planning, design, and construction.
 The rose-tinted glass on the building's facade permits the maximum entry of daylight and warmth in the winter, and conserves cooling by reflecting heat in the summer.
 The strength of the precast of poured concrete means fewer interior walls. Both the numerous, large windows and the minimal use of walls and partitions allow a view for almost everyone, and help create an open and collaborative working environment.
 The entrance of Building 430 leads into a building-width, three- story atrium and reception area. The centerpiece of the atrium is a dramatic, freestanding, cantilevered staircase, climbing from the marble-chip terrazzo main floor to the skylight-covered third floor.
 The new building also features a 120-person seminar room, two conference rooms, two employee break rooms, a computer training center, and a fully integrated computer data collection and communications network, and up to 30 laboratory areas.
 Through its scientific and medical innovations over the years, Sandoz Pharmaceuticals has made significant contributions in many important areas of medicine, such as organ transplantation, the management of headache pain, mental illness, sleep disturbances, geriatrics, parkinson's disease, allergic/respiratory disorders, and obstetrics.
 Leading prescription products marketed by Sandoz include: Sandimmune, an anti-rejection drug that revolutionized organ transplantation; Clozaril for severe schizophrenia; DynaCirc for high blood pressure; Eldepryl and Parlodel for Parkinson's Disease; Restoril for insomnia; Florinal and D.H.E. 45 for migraine headaches; the Tavist line of allergy/cold products; and Sandostatin for controlling the symptoms of certain intestinal tumors.
 The company's OTC products include the Triaminic line of cough/cold products; Theraflu, a hot liquid medicine for flu, cold, and cough symptoms; the Ex-Lax line of laxatives; and, Gas-X tablets for relief of the symptoms of stomach and intestinal gas.
 Sandoz Pharmaceuticals Corporation is an operating division of Sandoz Corporation based in New York City, the U.S. affiliate of Sandoz International, Ltd.
 -0- 6/5/92
 /CONTACT: William J. O'Donnell of Sandoz Pharmaceutical, 201-503-7070/ CO: Sandoz Pharmaceuticals Corporation ST: New Jersey IN: MTC SU:


PS-OS -- NY036 -- 7467 06/05/92 12:40 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 5, 1992
Words:628
Previous Article:NORTHEAST UTILITIES-PSNH AFFILIATION COMPLETED
Next Article:NBI ANNOUNCES LAYOFFS
Topics:


Related Articles
CHRONIMED APPOINTED BY SANDOZ TO ADMINISTER PATIENT DRUG USE STUDY
SANDOZ PHARMACEUTICALS NAMES TIM ROTHWELL PRESIDENT AND CEO
SANDOZ PHARMACEUTICALS CORP. AND VALUE HEALTH INC. SIGN LETTER OF INTENT: WILL WORK WITH TRANSPLANT COMMUNITY TO ENHANCE PATIENT CARE
Sandoz Announces Plans to Double Permanent Sales Force
Novartis Announces Future United States Health Care Manufacturing and Distribution System
FDA inspections confirm GMP compliance at EaglePicher Pharmaceutical Services.
Sandoz Inc. Launches Generic Rebetol.
Sandoz Inc. Launches Generic Rebetol.
Geneva Pharmaceuticals, Inc., Renamed Sandoz, Inc. - New Name Symbolizes Global Strength -.
Monsanto Seeks Over $100 Million in Damages Arising From Novartis Subsidiary Failure to Meet FDA Quality Standards.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters